Table 1.
Data summary
| Variable | Total | Healthy control | PD-Normal | PD-MCI | PDD | P-value |
|---|---|---|---|---|---|---|
| n = 165 | n = 17 | n = 45 | n = 86 | n = 17 | ||
| Gender, female/male, n (%) | 52 (32)/113 (68) | 10 (59)/7 (41) | 22 (49)/23 (51) | 17 (20)/69 (80) | 3 (18)/14 (82) | <0.0001a |
| Age, years, mean (SD) | 66.8 (8.32) | 65.06 (6.7) | 64.4 (7.6) | 67.8 (8.3) | 69.5 (10.3) | nsb |
| Disease duration, years, mean (SD) | – | – | 4.6 (3.9) | 5.6 (5.6) | 7.5 (4.8) | nsc |
| MoCA score, mean (SD) | 24.6 (3.9) | 27.4 (2.0) | 27.1 (2.3) | 24.1 (2.5)*, ^ | 17.8 (5.1)#, ^ ,† | <0.0001c |
| MDS-UPDRS, part III OFF, mean (SD) | 26.8 (16.4) | 1.18 (1.5) | 29.1 (14.6) | 27.5 (13.8) | 43.2 (12.5)$,† | <0.0001c,d |
| APOE ε4 allele, % carriage | 23.0 | 17.6 | 32.6 | 19.8 | 20.0 | nsa |
a
Chi-square test.
b
One-way ANOVA post hoc significances for age: PD-Normal versus PDD P < 0.05.
c
Kruskall-Wallis test.
d
Kruskall-Wallis test comparing Parkinson’s disease subgroups only.
*
P < 0.001 versus Control; #P < 0.0001 versus Control; ^P < 0.0001 versus PD-Normal; $P < 0.01 versus PD-Normal; &P < 0.01 versus PD-MCI; †P < 0.001 versus PD-MCI. ns = not significant.